(Q35939955)

11 August 2017

1 reference

title

Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease (English)

1 reference

11 August 2017

Stephen Y Chang

1

1 reference

11 August 2017

Colin W Howden

series ordinal

2

1 reference

11 August 2017

publication date

1 December 2004

1 reference

Current gastroenterology reports

11 August 2017

published in

1 reference

11 August 2017

volume

6

1 reference

11 August 2017

issue

6

1 reference

11 August 2017

page(s)

447-453

1 reference

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

11 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11894-004-0066-6

Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11894-004-0066-6

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11894-004-0066-6

COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice

21 January 2018

1 reference

12 December 2020

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

12 December 2020

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

12 December 2020

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

1 reference

12 December 2020

COX-1-sparing NSAIDs--is the enthusiasm justified?

1 reference

12 December 2020

Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases

1 reference

12 December 2020

Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States

1 reference

12 December 2020

Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans

1 reference

12 December 2020

Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs

1 reference

12 December 2020

Recent considerations in nonsteroidal anti-inflammatory drug gastropathy

1 reference

12 December 2020

Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study

1 reference

12 December 2020

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

12 December 2020

Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans

1 reference

12 December 2020

Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs.

1 reference

12 December 2020

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

1 reference

12 December 2020

Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis

1 reference

12 December 2020

NSAIDs: the emperor's new dogma?

1 reference

12 December 2020

No-Aspirin (NCX 4016)

1 reference

12 December 2020

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

12 December 2020

Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole

1 reference

12 December 2020

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

12 December 2020

Underutilization of preventive strategies in patients receiving NSAIDs

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

1 reference

12 December 2020

10.1007/S11894-004-0066-6

Identifiers

DOI

1 reference

11 August 2017

1 reference